

Unknown

From: Schwartz, Jack A
Sent: Monday, November 08, 2004 9:31 AM
To: Jones, Martin AM (Seroquel); Melville, Margaret G
Cc: Brecher, Martin; Mullen, Jamie A
Subject: FW: Quetiapine study

Martin and Meg,

We have a trial 31 investigator seeking information regarding the results from this study, which have not been presented or published. We need to respond to this investigator. I believe we should come to an agreed position within the GPT regarding this study as well as the numerous other early studies.

Can we please have this as an strategy agenda item at our next meeting.

Thanks,
Jack

-----Original Message-----

From: Tumas, John A
Sent: Monday, November 08, 2004 8:30 AM
To: Schwartz, Jack A; Mullen, Jamie A
Subject: RE: Quetiapine study

Jack,

I'm not aware of one.

John

-----Original Message-----

From: Schwartz, Jack A
Sent: Monday, November 08, 2004 7:57 AM
To: Tumas, John A; Mullen, Jamie A
Subject: RE: Quetiapine study


Do we have an agreed position regarding this trial?

Thanks,
Jack

-----Original Message-----

From: Ortiz, Nancy
Sent: Friday, November 05, 2004 10:33 AM
To: Tumas, John A; Mueller, Karin; Mullen, Jamie A; Schwartz, Jack A
Subject: RE: Quetiapine study

I understand that this trial has not been published, however one of my KOLS (also one of the co-investigators) is asking for info..what should I communicate to him regarding this trial. What is the company's response?



Nancy

Nancy Ortiz, PharmD., RPh
Sr. Medical Information Scientist-CNS
AstraZeneca LP/Scientific Affairs
voice mail: 800.822.9209 x60083
office: 201.224.8237
fax: 201.224.8257
email: Nancy.Ortiz@astrazeneca.com

CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

-----Original Message-----

From: Tumas, John A
Sent: Thursday, November 04, 2004 8:44 AM
To: Mueller, Karin; Ortiz, Nancy; Mullen, Jamie A; Schwartz, Jack A
Subject: RE: Quetiapine study

Hi Karin,

Trial 31 was never published or presented anywhere.

John

-----Original Message-----

From: Mueller, Karin
Sent: Thursday, November 04, 2004 6:36 AM
To: Tumas, John A; Ortiz, Nancy
Subject: FW: Quetiapine study

John

Do we have a publication or poster on this. This was before my time.

Thanks-Karin

-----Original Message-----

From: Ortiz, Nancy
Sent: Wednesday, November 03, 2004 9:32 AM
To: Mueller, Karin
Subject: Quetiapine study

Hi Karin:

I hope you are doing well. I need your assistance. My KOL Leslie Citrome has requested the following info (see email below)...how can I obtain this info....according to John Renna the results were not positive and were not published...what do you recommend I tell Citrome?

Here is Citrome's email...

Aside from the Emsley paper there was another treatment resistant schizophrenia trial. I was a sub-investigator to Dr. Lindenmayer at the RPC/NKI site for that study (Dr. Lindenmayer ran the study at MPC). I have not heard anything about that study since we completed it

years ago. There were 28 centers involved and I think the last patient was enrolled in 1996.

The study title was "A Multicenter, Double-Blind, Randomized, Comparison of ICI 204,636 (SEROQUEL) and Chlorpromazine in the Treatment of Subjects With Treatment-Resistant Schizophrenia". The protocol is dated April 13, 1994, with Revision 1 October 18, 1994 and Revision 2 September 12, 1995. Protocol number is 5077IL/0031:0018

can I get a study result?

Nancy

Nancy Ortiz, PharmD., RPh
Sr. Medical Information Scientist-CNS
AstraZeneca LP/Scientific Affairs
voice mail: 800.822.9209 x60083
office: 201.224.8237
fax: 201.224.8257
email: Nancy.Ortiz@astrazeneca.com

CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for the sole use of the intended recipient (s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.